Allergic rhinitis and allergic asthma
Conditions
Interventions
AIT Treatment Group:AIT treatment with Alutard SQ for 3 years
Sponsors
The Third Affiliated Hospital of Sun Yat-sen University
Eligibility
Sex/Gender
All
Age
5 Years to 18 Years
Inclusion criteria
Inclusion criteria: ? Age: over 5 years old, less than 15 years old; ? Children who met the diagnostic criteria of allergic rhinitis, bronchial asthma, and allergic rhinitis combined with asthma in Chinese Guidelines for the Diagnosis and Treatment of Allergic Rhinitis 2015 [16] and Chinese Guidelines for the diagnosis and treatment of Allergic Asthma [17]; ? Confirmed presence of dust mite allergen positive: dermatophagoides pteronyssinus skin prick test showed house dust mite ++ or above; Or the allergen test showed grade 2 or above house dust mite specific IgE; ? no recent severe asthma attack or other serious allergic diseases. ? Parents or guardians agreed to AIT treatment and signed written informed consent.
Exclusion criteria
Exclusion criteria: ?severe or uncontrolled asthma [forced expiratory volume in 1 second (FEV1) < 70% predicted]; ?patients who could not control their symptoms or whose lung function continued to decrease with the use of grade 4 or 5 asthma control regimens; ? two consecutive episodes of unexplained anaphylaxis during immunotherapy; ? patients receiving ß-blockers, angiotensin-converting enzyme inhibitors (ACEI) or monoamine oxidase inhibitors; ? patients with serious cardiovascular and cerebrovascular diseases, immune diseases (including autoimmune diseases and immunodeficiency diseases), malignant diseases and chronic infectious diseases; ? patients with severe psychological illness, poor compliance, or inability to understand the risks and limitations of treatment. ? patients who had received previous allergen specific immunotherapy ? poor patient compliance or other conditions considered by the investigator to be inappropriate for participating in the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Serum Der p, Der p 1, and Der p 2 specific IgE;Serum and saliva Der p, Der p 1, and Der p 2 specific IgG4;Serum and saliva Der p 1, and Der p 2 specific IgG1;Serum Der p specific IgE blocking factor ;Symptom & VAS score;RQLQ ; | — |
Countries
China
Contacts
Public ContactChen Zhuanggui
Third Affiliated Hospital of Sun Yat-sen University
Outcome results
None listed